Screening for Drug-Induced Endothelial Dysfunction: Clinical Relevance, Evidence, and Emerging Strategies

Abstract

Drug-induced endothelial dysfunction (DIED) is increasingly recognized as a critical factor in the pathogenesis of cardiovascular complications associated with a wide range of pharmacological agents. This review synthesizes current evidence on the epidemiology, mechanisms, clinical presentation, diagnostic strategies, and management of DIED, emphasizing recent advances and guideline-based recommendations. Special focus is placed on the importance of early screening and intervention to mitigate morbidity and mortality in at-risk populations, with practical implications for clinicians and healthcare systems.

Introduction

The vascular endothelium plays a central role in maintaining hemostatic balance, vascular tone, and immune modulation. Pharmacological agents, while essential in disease management, may adversely affect endothelial function, resulting in heightened cardiovascular risk. Drug-induced endothelial dysfunction is an underappreciated but potentially reversible contributor to atherogenesis, thrombosis, and end-organ damage. In the era of polypharmacy and expanding therapeutic modalities, systematic screening for DIED is vital for optimizing patient outcomes and guiding therapeutic decisions.

Epidemiology / Disease Burden

The prevalence of DIED is challenging to quantify due to under-recognition, lack of standardized diagnostic protocols, and variability in reporting. However, studies suggest that up to 30% of patients receiving certain chemotherapeutic agents, immunosuppressants, or psychotropic medications exhibit evidence of endothelial impairment. Cardiovascular morbidity attributable to DIED is particularly significant in oncologic, rheumatologic, and psychiatric populations. The burden is amplified in elderly patients, those with multimorbidity, and individuals with pre-existing cardiovascular disease, underscoring the need for vigilant monitoring and early intervention.

Pathophysiology

DIED arises from multifactorial mechanisms involving direct cytotoxic effects, oxidative stress, inflammatory activation, and altered nitric oxide bioavailability. Agents such as anthracyclines, tyrosine kinase inhibitors, calcineurin inhibitors, and certain antipsychotics disrupt endothelial homeostasis through increased reactive oxygen species production, mitochondrial injury, and upregulation of pro-inflammatory cytokines. The resultant endothelial activation promotes leukocyte adhesion, increased permeability, vasoconstriction, and prothrombotic milieu, ultimately accelerating vascular injury and atherogenesis.

Risk Factors

Risk factors for DIED include traditional cardiovascular risk factors (hypertension, diabetes mellitus, dyslipidemia, smoking), advanced age, male sex, renal dysfunction, and polypharmacy. Genetic predispositions affecting drug metabolism, co-administration of multiple endothelium-impairing agents, and longer duration or higher doses of offending drugs further amplify risk. Recognizing these risk factors is essential for personalized risk stratification and tailored screening strategies.

Clinical Features

Clinical manifestations of DIED are often subtle and nonspecific, ranging from asymptomatic endothelial impairment to overt vascular events such as hypertension, thromboembolism, or accelerated atherosclerosis. Endothelial dysfunction may precede clinical cardiovascular disease by years, highlighting the importance of proactive screening. In the context of chemotherapy, transplant immunosuppression, or long-term psychotropic therapy, new-onset hypertension, proteinuria, or unexplained vascular events should prompt evaluation for DIED.

Diagnosis

Diagnostic evaluation integrates clinical suspicion, risk profiling, and objective assessment of endothelial function. Non-invasive modalities such as flow-mediated dilation (FMD) of the brachial artery, peripheral arterial tonometry (PAT), and measurement of circulating biomarkers (e.g., von Willebrand factor, asymmetric dimethylarginine) provide surrogate markers of endothelial health. In select cases, imaging of vascular reactivity or microvascular function may be warranted. Importantly, diagnosis requires exclusion of alternative etiologies and consideration of temporal associations with drug initiation or dose escalation.

Treatment & Management

Management of DIED hinges on prompt identification, withdrawal or substitution of the offending agent where feasible, and aggressive modification of cardiovascular risk factors. Pharmacological interventions such as statins, ACE inhibitors, or antioxidants have demonstrated benefit in ameliorating endothelial dysfunction in select settings. Optimizing blood pressure, glycemic control, and lipid profile remains foundational. Multidisciplinary collaboration between prescribers, cardiologists, and pharmacists is crucial to balancing therapeutic benefit against vascular risk.

Recent Advances / Emerging Therapies

Recent advancements include the development of sensitive endothelial function assays, genetic screening for drug susceptibility, and the identification of novel biomarkers predictive of DIED. Emerging therapies focus on targeted antioxidant strategies, endothelial progenitor cell modulation, and pharmacological agents that restore nitric oxide signaling. Ongoing trials are evaluating the role of SGLT2 inhibitors, GLP-1 receptor agonists, and selective cytokine blockers in reversing drug-induced vascular injury, offering hope for future therapeutics tailored to individual risk.

Guideline Recommendations

Current guidelines emphasize the importance of baseline and periodic cardiovascular risk assessment in patients initiating drugs known to impair endothelial function. The European Society of Cardiology and American Heart Association recommend integrating non-invasive endothelial function testing in high-risk cohorts, particularly in oncology and transplant populations. Shared decision-making, patient education, and close monitoring for vascular adverse events are strongly advocated. Guidelines also highlight the need for prospective registries and research to refine screening protocols and outcome measures.

Conclusion

Screening for drug-induced endothelial dysfunction is an essential, yet underutilized, strategy in contemporary clinical practice. Early detection allows for timely intervention, reduces cardiovascular morbidity, and supports the safe use of necessary pharmacotherapies. Integrating mechanism-based risk stratification, advanced diagnostic tools, and multidisciplinary collaboration will enhance patient safety and inform evidence-based prescribing. Continued research and guideline evolution are needed to optimize screening algorithms and therapeutic outcomes in this emerging domain of vascular medicine.